Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Inclusion Criteria: * All patients (age \> 18 years) will have locally recurrent gynecological cancer with a component of disease that will fit within a standard RT portal at the time of presentation * ECOG performance status score 0-1 * All patients will have had a prior hysterectomy * Histological confirmation of recurrent gynecological cancer, including adenocarcinoma, papillary serous carcinoma, clear cell carcinoma, or carcinosarcoma * Age \> 18 years * Radiologic work-up computer tomography of the chest and abdomen, and computer tomography or MR of the pelvis confirming pelvis-confined recurrence * Adequate renal function as evidenced by serum creatinine \< 1.5 mg/dL * Adequate hepatic function as evidenced by: Serum total bilirubin \< 1.5 mg/dL SGOT/SGPT \< 3X the ULN for the reference lab * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Patients with a prior history of full course external beam radiation therapy to the pelvis (patients with prior vaginal brachytherapy may be included) * Inability to comply with study and/or follow-up procedures * Life expectancy of less than 12 weeks * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored avastin cancer study * Known CNS disease (including history of encephalitis, multiple sclerosis or seizure disorder), except for treated brain metastasis * Inadequa…